Viatris (MEX:MYL) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MYL Viatris Inc MEX:MYL
54 GF Score
Price MXN280.00
GF Value MXN197.95
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Viatris Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Viatris's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was MXN32,400 Mil. Viatris's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was MXN205,704 Mil. Viatris's annualized EBITDA for the quarter that ended in Jun. 2026 was MXN50,662 Mil. Viatris's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 4.70.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Viatris's Debt-to-EBITDA or its related term are showing as below:

MEX:MYL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -37.17   Med: 4.94   Max: 13.13
Current: 5.2

During the past 13 years, the highest Debt-to-EBITDA Ratio of Viatris was 13.13. The lowest was -37.17. And the median was 4.94.

MEX:MYL's Debt-to-EBITDA is ranked worse than
82.72% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs MEX:MYL: 5.20

Viatris  (MEX:MYL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Viatris Debt-to-EBITDA Related Terms

Viatris Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Viatris's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Debt-to-EBITDA Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Viatris Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MEX:MYL vs NBIX, UTHR, ELAN: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Viatris's Debt-to-EBITDA falls into.


MEX:MYL
54GF Score
Viatris Inc MEX:MYL
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Viatris's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(36726.72465 + 227597.09665) / -8878.2534
=-29.77

Viatris's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(32399.82725 + 205704.47975) / 50661.76724182
=4.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Viatris (MEX:MYL) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of MXN280.00 is trading 41.4% above its estimated GF Value™ of MXN197.95. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for MEX:MYL:

  • Debt-to-EBITDA:
  • GF Value™: MXN197.95 vs. price of MXN280.00 (41.4% above fair value)
  • GF Score™: 54/100 with 8 warning signs

No single metric tells the full story. See the MEX:MYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
54GF Score

Get the complete analysis for MEX:MYL

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN280.00
Price
MXN197.95
GF Value